Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

UPDATE - INVESTOR ALERT: Levi & Korsinsky, LLP Commences an Investigation of the Board of Directors of SALIX PHARMACEUTICALS, LTD. In Connection With the Fairness of the SALE OF THE COMPANY TO VALEANT PHARMACEUTICALS INTERNATIONAL, INC. -- SLXP

NEW YORK, Feb. 24, 2015 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP:

Protecting the Rights of Shareholders

TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED COMMON STOCK OF SALIX PHARMACEUTICALS, LTD. (NasdaqGS: SLXP) ("Salix" or "the Company") PRIOR TO FEBRUARY 23, 2015 AND CONTINUE TO HOLD SUCH SHARES.

YOU ARE HEREBY NOTIFIED that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Salix to Valeant Pharmaceuticals International.  Click here to learn more about the investigation: http://zlk.9nl.com/salix. There is no cost or obligation to you.

The Board of Directors of Salix agreed to sell the Company to Valeant Pharmaceuticals. Under the terms of the transaction, Salix shareholders will receive $158.00 in cash for each Salix common share they own. The investigation concerns whether the Board of Salix breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Valeant Pharmaceuticals International is underpaying for Salix shares.

If you own Salix common stock and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/salix.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (866) 367-6510
www.zlk.com

Photo - http://photos.prnewswire.com/prnh/20120409/MM84375LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/update---investor-alert-levi--korsinsky-llp-commences-an-investigation-of-the-board-of-directors-of-salix-pharmaceuticals-ltd-in-connection-with-the-fairness-of-the-sale-of-the-company-to-valeant-pharmaceuticals-international-300040635.html

SOURCE Levi & Korsinsky, LLP



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today